Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Melanoma 3Neoplasm Metastasis 2Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × omaveloxolone × Clear all
NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

Biogen

Phase 1/2 Completed
41 enrolled 15 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03593499 2025-05-31

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

Biogen

No longer available
Dermatologic

Melanoma

NCT02029729 2025-05-29

DISCOVER

Biogen

Phase 1 Completed
11 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡